Typewriter Therapeutics
All-RNA genetic medicines with site-specific, non-viral gene insertion
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Typewriter Therapeutics develops genetic medicines using an all-RNA platform that inserts full-length therapeutic genes at a natural safe-harbor site without viral vectors or double-strand breaks. The company, with operations in Cambridge, Massachusetts and Tokyo, is advancing applications including in vivo engineered CAR-T cells and gene insertion to the liver for severe rare disease. Its science builds on foundational R2 retrotransposon research from the University of Tokyo and the University of Rochester. Public site: https://typewritertx.com/
- Website
- typewritertx.com
- Stage
- series-a
- Founded
- 2022
- Location
- Cambridge, MA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Typewriter TPRT Platform — Non-viral, RNA-delivered platform for site-specific whole-gene insertion · Other